A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Karen Ballen, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00580242
First received: December 20, 2007
Last updated: March 6, 2012
Last verified: March 2012
  Purpose

This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination with lenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle for patients with myelodysplastic syndrome.


Condition Intervention Phase
Myelodysplasia
Drug: Bortezomib
Drug: Lenalidomide
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalating Study of Bortezomib and Lenalidomide in Patients With Untreated or Previously Treated, Primary and Secondary Non 5q- Del Myelodysplasia

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Establish the maximally tolerated dose of bortezomib, up to 1.3 mg/m2/day, that can be administered in combination with lenalidomide in patients with primary and secondary non 5q del myelodysplasia who are untreated or previously treated. [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess efficacy in terms of the number of patients experiencing a decrease in blast percentage [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: No ]
  • Assess efficacy in terms of the number of patients experiencing a decrease in transfusion requirements [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: No ]
  • Determine the toxicity profile of bortezomib when used in combination with lenalidomide for patients with myelodysplasia [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: Yes ]
  • Determine the time (days) to transfusion independence [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: No ]
  • Determine the duration of response [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: No ]
  • Determine if molecular markers can predict responsiveness to treatment (for consenting patients) [ Time Frame: 3, 6 and 9 months ] [ Designated as safety issue: Yes ]

Enrollment: 23
Study Start Date: November 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
Drug: Bortezomib
First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Other Name: Velcade
Drug: Bortezomib
Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Other Name: Velcade
Drug: Bortezomib
Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Other Name: Velcade
Drug: Lenalidomide
Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
Other Name: Revlimid

Detailed Description:

Currently, there are no curative therapies for myelodysplasia except for allogeneic stem cell transplantation. Both lenalidomide and bortezomib have activity as single agents in patients with myelodysplasia. This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination withlenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle. The planned bortezomib doses have been evaluated in previous Phase I clinical studies in similar patient populations and have been safe and well tolerated in a twice-weekly schedule of administration. Lenalidomide has been shown to have efficacy in myelodysplasia. The combination of lenalidomide and bortezomib has been used in patients with multiple myeloma.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients may be untreated or previously treated.
  • Age > 18 years
  • Able to adhere to study schedule and other protocol requirements
  • Unequivocal clinicopathologic diagnosis of myelodysplastic syndrome, non 5q- deletion.
  • Patients may have had prior chemotherapy or radiotherapy for another malignancy or myelodysplasia as long as it was completed at least 4 weeks (6 weeks for nitrosureas) prior to initiation of therapy.
  • ECOG performance status of 0-2 (Appendix 10.3)
  • Life expectancy greater than 3 months
  • Total bilirubin ≤ 2.0 mg/dl, ALT and AST ≤ 3 X the upper limit of normal (ULN), creatinine < 2.0 mg/dl all within 28 days prior to enrollment.
  • Patients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Absolute neutrophil count > 0.5 x 10 (9)/l
  • Platelet count > 30 x 10 (9)/l
  • Prior treatment with 5-azacytidine is encouraged, but not required.
  • Patients may have had prior treatment for MDS, including single agent lenalidomide or bortezomib.
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50mIU/ml within 10-14 days prior to and within 24 hours of prescribing lenalidomide and must commit to abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control,at least 4 weeks before starting taking lenalidomide. FCBP must agree to ongoing pregnancy testing. Men must agree not to father a child and agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy.
  • All study participants must be registered into the mandatory RevAssist Program®, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria:

  • Ejection fraction < 40%
  • Patients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the consent form.
  • Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Patients with major surgery within the 28 days prior to trial enrollment.
  • Patients with ≥ Grade 2 peripheral neuropathy or active herpes infection
  • Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cirrhosis, chronic obstructive or restrictive pulmonary disease, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrythmia.
  • Patients with secondary MDS that require concurrent therapy for the primary cancer diagnosis.
  • The development of erythema nodosum as characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Patient with hypersensitivity to bortezomib, boron or mannitol.
  • Female subject is pregnant or breast-feeding. . Lactating females must agree not to breast feed while taking lenalidomide.
  • Patient has received an investigational drug within 28 days of enrollment.
  • Known hypersensitivity to thalidomide or lenalidomide
  • Concurrent use of other anti-cancer agents or treatments.
  • Known positive for HIV
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580242

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Celgene Corporation
Dana-Farber Cancer Institute
Investigators
Principal Investigator: Karen Ballen, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Karen Ballen, Director, Leukemia Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00580242     History of Changes
Other Study ID Numbers: 07-006, RV-MDS-PI-0161
Study First Received: December 20, 2007
Last Updated: March 6, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Myelodysplasia

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Bortezomib
Lenalidomide
Thalidomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on April 23, 2014